506 related articles for article (PubMed ID: 24780456)
1. Blood pressure, hypertension, RAAS blockade, and drug therapy in diabetic kidney disease.
Yamout H; Lazich I; Bakris GL
Adv Chronic Kidney Dis; 2014 May; 21(3):281-6. PubMed ID: 24780456
[TBL] [Abstract][Full Text] [Related]
2. Albuminuria: a target for treatment of type 2 diabetic nephropathy.
de Zeeuw D
Semin Nephrol; 2007 Mar; 27(2):172-81. PubMed ID: 17418686
[TBL] [Abstract][Full Text] [Related]
3. [Risk and prevention of diabetic nephropathy].
Ravera M; Re M; Deferrari G
G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
[TBL] [Abstract][Full Text] [Related]
4. Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers) in diabetic nephropathy.
Jacobsen P; Rossing K; Parving HH
Curr Opin Nephrol Hypertens; 2004 May; 13(3):319-24. PubMed ID: 15073491
[TBL] [Abstract][Full Text] [Related]
5. Dual blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy: the role of aldosterone.
Schjoedt KJ; Jacobsen P; Rossing K; Boomsma F; Parving HH
Horm Metab Res; 2005 Apr; 37 Suppl 1():4-8. PubMed ID: 15918104
[TBL] [Abstract][Full Text] [Related]
6. Aggressive blood pressure reduction and renin-angiotensin system blockade in chronic kidney disease: time for re-evaluation?
Sarafidis PA; Ruilope LM
Kidney Int; 2014 Mar; 85(3):536-46. PubMed ID: 24048382
[TBL] [Abstract][Full Text] [Related]
7. Angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers for prevention and treatment of nephropathy associated with type 2 diabetes mellitus.
Hughes DB; Britton ML
Pharmacotherapy; 2005 Nov; 25(11):1602-20. PubMed ID: 16232022
[TBL] [Abstract][Full Text] [Related]
8. The renin-angiotensin system and diabetic nephropathy.
Gurley SB; Coffman TM
Semin Nephrol; 2007 Mar; 27(2):144-52. PubMed ID: 17418683
[TBL] [Abstract][Full Text] [Related]
9. [Control of arterial pressure in diabetic nephropathy].
Luño J; García de Vinuesa S
Nefrologia; 2001; 21(3):240-5. PubMed ID: 11471304
[No Abstract] [Full Text] [Related]
10. Management of renin-angiotensin system blockade in patients with chronic kidney disease under specialist care. Retrospective cross-sectional study.
Tylicki L; Jakubowska A; Lizakowski S; Świetlik D; Rutkowski B
J Renin Angiotensin Aldosterone Syst; 2015 Mar; 16(1):145-52. PubMed ID: 25324423
[TBL] [Abstract][Full Text] [Related]
11. Improving microvascular outcomes in patients with diabetes through management of hypertension.
McGill JB
Postgrad Med; 2009 Mar; 121(2):89-101. PubMed ID: 19332966
[TBL] [Abstract][Full Text] [Related]
12. Effects of renin-angiotensin system blockers on renal outcomes and all-cause mortality in patients with diabetic nephropathy: an updated meta-analysis.
Sarafidis PA; Stafylas PC; Kanaki AI; Lasaridis AN
Am J Hypertens; 2008 Aug; 21(8):922-9. PubMed ID: 18535536
[TBL] [Abstract][Full Text] [Related]
13. Limitations of angiotensin inhibition.
Nobakht N; Kamgar M; Rastogi A; Schrier RW
Nat Rev Nephrol; 2011 Jun; 7(6):356-9. PubMed ID: 21502972
[TBL] [Abstract][Full Text] [Related]
14. [RAS blockade in diabetic nephropathy. "Early intervention can dramatically decrease loss of function].
Ritz E
MMW Fortschr Med; 2004 Sep; 146(38):12. PubMed ID: 15532423
[No Abstract] [Full Text] [Related]
15. The renin-angiotensin-aldosterone system and its blockade in diabetic nephropathy: main focus on the role of aldosterone.
Schjoedt KJ
Dan Med Bull; 2011 Apr; 58(4):B4265. PubMed ID: 21466768
[TBL] [Abstract][Full Text] [Related]
16. Renin-angiotensin-aldosterone system blockade and renal protection: angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers?
Ruilope LM
Acta Diabetol; 2005 Apr; 42 Suppl 1():S33-41. PubMed ID: 15868118
[TBL] [Abstract][Full Text] [Related]
17. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
[TBL] [Abstract][Full Text] [Related]
18. The RAAS in the pathogenesis and treatment of diabetic nephropathy.
Ruggenenti P; Cravedi P; Remuzzi G
Nat Rev Nephrol; 2010 Jun; 6(6):319-30. PubMed ID: 20440277
[TBL] [Abstract][Full Text] [Related]
19. [Nephroprotection by inhibition of the renin-angiotensin system--wish or reality?].
Barnas U; Mayer G
Wien Klin Wochenschr; 1995; 107(1):10-4. PubMed ID: 7871784
[TBL] [Abstract][Full Text] [Related]
20. Evidence for renoprotection by blockade of the renin-angiotensin-aldosterone system in hypertension and diabetes.
Karalliedde J; Viberti G
J Hum Hypertens; 2006 Apr; 20(4):239-53. PubMed ID: 16452996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]